Floatz logo

Selinexor

Advanced Triple Negative Breast Cancers

National University Hospital, SingaporeSmall moleculePhase 1/2Active
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
95/ 100

Competitive context

447 Active assets in the Advanced Triple Negative Breast Cancers cohort.

Asset / SponsorPhaseRating
Capivasertib
AstraZeneca
Phase 3BB
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 4BB
Carboplatin
M.D. Anderson Cancer Center
Phase 4BB
Veliparib
National Cancer Institute (NCI)
Phase 3BB
Atezolizumab
European Institute of Oncology
Phase 3BB

View all 50 →

Same molecule, other indications

Selinexor is also rated in:

diffuse large B-cell lymphomaDormant
BBB
Indicative ·
72 / 100
View asset →
mantle cell lymphomaDormant
BB
Indicative ·
70 / 100
View asset →
relapsed/refractory diffuse large B-cell lymphomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →